CHD1 and cancer: In this study, we investigated an expanded cohort of more than 6800 PCa patients who underwent radical prostatectomy (RP) to determine by multivariate analyses the potential influence of the CHD1 deletion on the postoperative metastasis-free survival (MFS), BCR-free survival, and cancer-specific survival (CSS).